The American Journal of Managed Care

Amivantamab Plus Chemotherapy Delivers Durable Responses in RAS/BRAF Wild-Type mCRC: Filippo Pietrantonio, MD

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
CURE

FDA Grants Breakthrough Status to Zoldonrasib in Lung Cancer

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...
Seeking Alpha

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...
The American Journal of Managed Care

GLP-1s More Effective at Preventing Colorectal Cancer Than Aspirin

Benefits of GLP-1 RAs were consistent across age groups and BMI categories, with semaglutide showing significant efficacy. These results were presented during the press briefing ahead of the 2026 ...
GEN

Pancreatic Cancer Drug Candidate Targets Elusive, but Common, K-Ras Variant

K-Ras mutations are all too familiar as drivers of cancer. And until recently, they were considered all but undruggable. But ever since the arrival of sotorasib and adagrasib—two FDA-approved ...
News Medical

New drug combo shows promise in targeting RAS-mutant multiple myeloma

The combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows. The work addressed multiple myeloma, a cancer that forms in blood cells that ...
Medscape

Secondary RAS Mutations Linked to Thyroid Cancer Severity, Mortality

MONTREAL — Key genetic mutations secondary to RAS mutations that are common in differentiated thyroid cancer (DTC) strongly correlate with higher risk and more advanced cancers, as well as ...